Payload Information
General Information of This Payload
| Payload ID | PAY0DDGJB |
|||||
|---|---|---|---|---|---|---|
| Name | IG-L-71 Payload |
|||||
| Synonyms |
IG-L-71 Payload
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C25H27N3O5 |
|||||
| Isosmiles | O=C1C2=C(CN1[C@@H](CCC3=O)C(N3)=O)C(OCC4=CC=C(CN5CCOCC5)C=C4)=CC=C2 |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C25H27N3O5/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27/h1-7,21H,8-16H2,(H,26,29,30)/t21-/m0/s1
|
|||||
| InChIKey |
IXZOHGPZAQLIBH-NRFANRHFSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
449.507 |
Polar area |
88.18 |
||
Complexity |
1028.208036 |
xlogp Value |
1.8588 |
|||
Heavy Count |
33 |
Rot Bonds |
6 |
|||
Hbond acc |
6 |
Hbond Donor |
1 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Cell-based Percent Inhibition (%) | 0 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 0 | % |
Vero C1008 cells
|
Normal
|
||
| Cellular activity | 22.1 | g | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 27.07 | % |
RPMI-8226 cells
|
Plasma cell myeloma
|
||
| Cellular activity | 517 | mm3 |
RPMI-8226 cells
|
Plasma cell myeloma
|
||
| Cellular activity | 7.9 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 88.8 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Percent Inhibition (%) | 9.41 | % | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.46 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 0.5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.59 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 1 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Degradation Concentration (DC50) | 1.7 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
||
| Half Maximal Effective Concentration (EC50) | >10000 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 111.6 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 12.8 | nM |
HEK293T cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13 | nM |
MM1.S cells
|
Plasma cell myeloma, Multiple myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 13 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 16000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 17 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >19952.62 | nM |
Vero C1008 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Degradation Concentration (DC50) | 2.4 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
MV4-11 cells
|
Childhood acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
Vero C1008 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 28 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3.8 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 60 | nM |
Sf9 cells
|
Normal
|
Each Antibody-drug Conjugate Related to This Payload